RxDoctor Payments DataLook up a doctor →

Ravi Rajan, MD

Urology · Lawrenceville, NJNPI 1831135078

Payments from drug & device makers

$79,307in general payments, 2019–2025

Across 421 payments — averaging $188.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$33K
  • Astellas Pharma US Inc$32K
  • Avyxa Pharma, LLC$4K
  • Johnson & Johnson$2K
  • Procept Biorobotics Corporation$1K
  • Myriad Genetic Laboratories, Inc.$1K
  • plus $7K from 43 others

What the payments were for

  • Consulting fees$1,3852%
  • Speaking & faculty fees$60,59076%
  • Travel & lodging$5,9508%
  • Food & beverage$11,25314%
  • Education$1290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$79,307 in reported general payments places this provider in the 90th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$654,103
Medicare patients
1,070
Services billed
10,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide50$644,588
GemtesaVibegron179$115,626
MyrbetriqMirabegron116$109,110
ElmironPentosan Polysulfate Sodium17$25,068
Tamsulosin Hcl777$11,109
XyostedTestosterone Enanthate16$9,439
Silodosin76$8,380
Finasteride512$7,709
Dutasteride91$3,715
Potassium Citrate ErPotassium Citrate34$3,331
Solifenacin Succinate87$3,265
Trospium Chloride ErTrospium Chloride11$2,975
Testosterone31$2,104
Desmopressin Acetate17$1,966
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst35$1,626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$31,539$753,698166 claims
Sumitomo Pharma America, Inc.Gemtesa$556$115,626179 claims
Antares Pharma, Inc.Xyosted$380$9,43916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 401 urology providers in New Jersey.

Other urology in Lawrenceville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →